Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin

Transplantation

Volumn 87, Issue 2, 2009, Pages 227-232

  Mai, Martin L ^a   Ahsan, Nasimul ^a   Wadei, Hani M ^a   Genco, Petrina V ^a   Geiger, Xochiquetzal J ^a   Willingham, Darrin L ^a   Taner, C Burcin ^a   Hewitt, Winston R ^a   Grewal, Hani P ^a   Nguyen, Justin H H ^a   Hughes, Christopher B ^a   Gonwa, Thomas A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Flow cytometry crossmatch positive; Intravenous immunoglobulin; Kidney transplantation

Indexed keywords

CLOTRIMAZOLE; CORTICOSTEROID; COTRIMOXAZOLE; CREATININE; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANEL REACTIVE ANTIBODY; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; ANTIBODY; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY;

ADULT; ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT INFECTION; GRAFT SURVIVAL; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; AGED; ALLOTRANSPLANTATION; ANIMAL; ANTIBODY SPECIFICITY; BLOOD; CYTOTOXICITY TEST; DRUG COMBINATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; LENGTH OF STAY; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; RABBIT; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; ANTILYMPHOCYTE SERUM; CYTOTOXICITY TESTS, IMMUNOLOGIC; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LENGTH OF STAY; MALE; MIDDLE AGED; RABBITS; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 59649100274     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31818c962b     Document Type: Article

References (37)

1. 1998 Annual Report of the US Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network; transplant data: 1988-1996. UNOS and the Division of Transplantation, Office of Special Programs, Richmond, VA. Health Resources and Services Administration, US Department of Health and Human Services, Rockville, MD; 1998.
2. U.S. Renal Data System. USRDS 2001 Annual Data Report: Atlas of end-stage renal disease in the United States. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD: 2001.
3. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605.
4. Bryan CF, Baier KA, Nelson PW, et al. Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric crossmatching. Transplantation 1998; 66: 1827.
5. Bryan CF, McDonald SB, Baier KA, et al. Flow cytometry beads rather than the antihuman globulin method should be used to detect HLA class I IgG antibody (PRA) in cadaveric renal regraft candidates. Clin Transplant 2002; 16(suppl 7): 15.
6. Garovoy MR, Rheinschmidt MA, Bigos M, et al. Flow cytometry analysis: A high technology cross-match technique facilitating transplantation. Transplant Proc 1983; 15: 1939.
7. Karpinski M, Rush D, Jeffery J, et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 2001; 12: 2807.
8. Mahoney RJ, Ault KA, Given SR, et al. The flow cytometric crossmatch and early renal transplant loss. Transplantation 1990; 49: 527.
9. Christiaans MH, Overhof R, ten Haaft A, et al. No advantage of flow cytometry crossmatch over complement-dependent cytotoxicityin immunologically well-documented renal allograft recipients. Transplantation 1996; 62: 1341.
10. Kerman RH, Susskind B, Buyse I, et al. Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome. Transplantation 1999; 68: 1855.
11. Lobashevsky AL, Senkbeil RW, Shoaf J, et al. Specificity of preformed alloantibodies causing B cell positive flow crossmatch in renal transplantation. Clin Transplant 2000; 14: 533.
12. Mahoney RJ, Norman DJ, Colombe BW, et al. Identification of high-and low-risk second kidney grafts. Transplantation 1996; 61: 1349.
13. Wen R, Wu V, Dmitrienko S, et al. Biomarkers in transplantation: Prospective, blinded measurement of predictive value for the flow cytometry crossmatch after negative antiglobulin crossmatch in kidney transplantation. Kidney Int 2006; 70: 1474.
14. Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: The Emory algorithm. Am J Transplant 2006; 6: 2307.
15. Vaidya S. Clinical importance of anti-human leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches. Transplantation 2008; 85: 1046.
16. Bielmann D, Honger G, Lutz D, et al. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 2007; 7: 626.
17. Gebel HM, Bray RA, Nickerson P.Pre-transplant assessment of donorreactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 2003; 3: 1488.
18. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033.
19. Glotz D, Haymann JP, Sansonetti N, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation 1993; 56: 335.
20. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76: 631.
21. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887.
22. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levelsof donor specific alloantibody. Am J Transplant 2006; 6:346.
23. Akalin E, Ames S, Sehgal V, et al. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients. Transplantation 2003; 76: 1444.
24. Jordan S, Vo A, Radha R, et al. Outcomes of highly sensitized (HS) patients transplanted with a cytotoxicity (CDC) negative, donor specific (DS) positive T-cell flow cytometry crossmatch using intravenous immunoglobulin (IVIG) induction. Am J Transplant 2005; 5: 159.
25. Pei R, Lee JH, Shih NJ, et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75: 43.
26. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria - An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
27. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
28. Cho YW, Cecka JM. Crossmatch tests - An analysis of UNOS data from 1991-2000. Clin Transpl 2001: 237.
29. Crespo M, Pascual M, Tolkoff-Rubin N, et al. Acute humoral rejection in renal allograft recipients. I. Incidence, serology and clinical characteristics. Transplantation 2001; 71: 652.
30. O'Rourke RW, Osorio RW, Freise CE, et al. Flow cytometry cross-matching as a predictor of acute rejection in sensitized recipients of cadaveric renal transplants. Clin Transplant 2000; 14: 167.
31. Scornik JC, Clapp W, Patton PR, et al. Outcome of kidney transplants in patients known to be flow cytometry crossmatch positive. Transplantation 2001; 71: 1098.
32. Utzig MJ, Blumke M, Wolff-Vorbeck G, et al. Flow cytometry cross-match: A method for predicting graft rejection. Transplantation 1997; 63: 551.
33. Gloor JM, DeGoey S, Ploeger N, et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004; 78: 221.
34. Akalin E, Bromberg JS. Intravenous immunoglobulin induction treatment in flow cytometry cross-match-positive kidney transplant recipients. Hum Immunol 2005; 66: 359.
35. LeFor WM, Ackermann JR, Alveranga DY, et al. Flow cytometry cross-matching and primary cadaver kidney graft outcome: Relevance of T and B cell targets, historic sera and autologous controls. Clin Transplant 1996; 10(6 Pt 2): 601.
36. Biswas M, Evans PJ. Acute anuric renal failure secondary to intravenous immunoglobulin in diabetic nephropathy.Diabetes Res Clin Pract 2007; 76: 139.
37. Wittstock M, Benecke R, Zettl UK. Therapy with intravenous immunoglobulins: Complications and side-effects. Eur Neurol 2003; 50: 172.